Newsroom

Tabletten
News
The German Center for Infection Research (DZIF) and the Helmholtz Centre for Infection Research (HZI) have developed a concept to form a National Alliance for Pandemic Therapeutics (NA-PATH). They thereby wish to target research and development of widely effective therapeutics in order to be better prepared for future outbreaks due to viral pathogens having pandemic potential. Overcoming the current COVID-19 pandemic will be considerably more difficult due to the deficiency of antiviral active substances.
06.10.2021
Infographic
Story
The Helmholtz Institute for One Health is a new HZI location in Greifswald, linking research into human and animal health with environmental factors.
04.10.2021
Gruppenbild
News
It often takes many years before a new active compound from basic research hits the market as a drug. In order to accelerate this process, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Saarland University will work together even more closely in the future. To this end, they have now founded the Translational Centre for Bioactive Compounds, in which scientists from both institutions will interact closely with the University Hospital in Homburg and the pharmaceutical industry.
02.10.2021
Luca Cicin-Sain
Interview
In the coronavirus pandemic, older people are particularly at risk from severe courses of COVID-19. However, other infectious diseases also affect them more than younger people. On the occasion of the International Day of Older Persons on 1 October, Prof Luka Cicin-Sain, Head of the Department "Viral Immunology", talks about the ageing of the immune system.
30.09.2021
Logos HZI und EMBL
News
EMBL and the six Helmholtz Centers of the Research Field Health (Helmholtz Health) are expanding their collaboration. The two research organisations are cooperating to expand the frontiers of health research and advance scientific progress for human health.
22.09.2021

HZI in the media

... des Leibniz Lungenzentrums Borstel, des Helmholtz-Instituts für Pharmazeutische Forschung Saarland sowie weiterer wissenschaftlicher ...

12.12.2025
|
Bionity.COM

angewiesen.“

 

Josef Penninger, Genetiker und wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung (HZI),

12.12.2025
|
Brandaktuell

Quelle:

 

Pressemitteilung Helmholtz-Zentrum für Infektionsforschung HZI ...

10.12.2025
|
LaborPraxis

Medikament Tolcapon identifiziert. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Kooperation ...

01.12.2025
|
Homburg

... wissenschaftlicher Ko-Direktor des Helmholtz Zentrums für Infektionsforschung (HZI). Thomas Pietschmann engagiert sich seit 2023 im ...

28.11.2025
|
juraforum.de

Dr. Alexander Titz, group leader at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). “Finding new ways to disrupt its

28.11.2025
|
ARCHYDE

... “, sagte die Leiterin der Epidemiologie am Braunschweiger Helmholtz-Zentrum für Infektionsforschung.

 

Lange betonte, flächendeckende ...

28.11.2025
|
Evangelische Zeitung

... ein Zentrum für Quantentechnologie entstehen und das Helmholtz-Institut für Pharmazeutische Forschung ausgebaut werden.

 

Mehr ...

27.11.2025
|
Tagesschau

Euro werden investiert in die Erweiterung des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS). Und ...

27.11.2025
|
ZEIT online

s drug tolcapone. HIPS is a site of the Helmholtz Center for Infection Research (HZI) in collaboration with Saarland University.

 

The

26.11.2025
|
Medical Xpress

... erhielt das Projekt „Citrapeutics“ vom Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig eine Förderung in Höhe ...

25.11.2025
|
Bionity.COM

led by Hannover Medical School (MHH) and the Helmholtz Center for Infection Research (HZI) has now discovered clear molecular signatures for

24.11.2025
|
Medical Xpress

Register now for the HZI-Newsletter